life and chemical sciences · the medical technologies (medtech) sector is the beating heart of...
TRANSCRIPT
Life and Chemical SciencesManufacturing Innovation
Life Sciences in
‘I am delighted that we have been able to showcase here 4 of Scotland’s leading themes in Manufacturing Innovation. The depth and breadth of the sector and the integrated Scottish ecosystems from academia to industry with Government support is quite unique globally. In addition to well-known organisations there are also many hidden jewels. This work builds on previous webinar programs, understanding the supportive funding landscape and leadership training on manufacturing innovation, technology commercialisation and scale-up’.
THE IMPORTANCE OF MANUFACTURING INNOVATIONThe Scottish Life and Chemical Sciences Manufacturing Strategy has set out a bold vision to strengthen the economy and bring business opportunities to Scotland.
In the revised 2025 vision for Scotland, we recognise and respond to the emerging global trends. The ageing population, proliferation of chronic diseases and increasing cost pressures on healthcare payers are now some of the biggest challenges for the Life Sciences sector. These new challenges are creating emerging markets and opportunities, such as:
• digital technologies, creating a paradigm shift in healthcare by assisting patients to be monitored and treated out-with the hospital setting through patient empowered healthcare management;• advances in genomics and big data, making the future for precision medicine, companion diagnostics, animal and crop health look bright; • developments in high value manufacturing, including the use of enzymes and continuous manufacturing techniques, driving down costs and creating opportunities for re-shoring production; and • innovations in the bio economy addressing environmental and food security concerns through industrial biotechnology, agritech and animal health.
CMACs Industrial Director Craig Johnston has led the Manufacturing Innovation theme within the Life and Chemical Sciences Manufacturing Strategy.
02 | Life and Chemical Sciences | Manufacturing Innovation
THE FUTURE AMBITION OF MANUFACTURING
Manufacturing Innovation has become a Scottish strength, showcased within the following technology sectors:
1. Continuous Manufacturing & Advanced Crystallisation2. Industrial Biotechnology3. Automation4. Cell and Gene TherapiesThese four sectors contribute to a diverse manufacturing innovation ecosystem in Scotland. This is illustrated through the technology roadmaps for each sector as well as industrial case studies demonstrating Scotland’s current status and future ambition.
In addition, Scotland has an expansive range of manufacturing innovation in other sectors including medical devices, vaccines and lightweight manufacturing.
The medical technologies (medtech) sector is the beating heart of Scotland’s life sciences. Scotland continues to demonstrate its ability to foster innovation and inspire novel medtech product and service development aimed at addressing global healthcare needs.
Also the vaccines market is expected to reach USD 49.27 Billion by 2022 from USD 34.30 Billion in 2017 and has seen further advancement in Scotland with the £44 Million GSK Montrose facility that is dedicated to produce material for millions of vaccines.
Further developing Scotland’s manufacturing abilities is the Lightweight Manufacturing Centre, becoming the first step towards creating a National Manufacturing Institute for Scotland (NMIS). It will focus on the manufacture of lightweight components for a range of industries in which lighter materials offer benefits, including, aerospace, automotive, oil and gas, renewables, medical, marine and off-highway transport. This will fill a significant gap in Scottish technical capability in light weighting and advanced materials development.
Life and Chemical Sciences | Manufacturing Innovation | 03
In ad
ditio
n to
core
pha
rmac
eutic
al ac
tiviti
es, C
MAC
wo
rks w
ith fo
od an
d ch
emica
l indu
stry
sect
ors,
an
exam
ple
of w
hich
is Sw
iss m
ulti-n
atio
nal a
grisc
ience
co
mpa
ny, S
ynge
nta w
ho h
ave
an im
porta
nt ac
tive
ingre
dien
t man
ufac
turin
g sit
e in
Gran
gem
outh
. To
geth
er th
ey e
valua
ted
the
crys
tallis
atio
n of
a m
ajor a
groc
hem
ical a
ctive
ingr
edien
t man
ufac
ture
d he
re in
Sco
tland
with
fund
ing su
ppor
t fro
m E
PSRC
.
Syng
enta
hav
e us
ed th
e im
prov
ed fu
ndam
enta
l un
ders
tand
ing fr
om th
e pr
ojec
t with
in its
own
de
velo
pmen
t pro
gram
to m
odel
and
furth
er d
evelo
p its
indu
stria
l pro
cess
. This
has
bot
h im
prov
ed th
e pr
oduc
tivity
and
cons
isten
cy o
f the
pro
duct
ion
proc
ess w
hich
has b
een
incor
pora
ted
into
on-g
oing
site
man
ufac
turin
g im
prov
emen
ts h
elping
to
tran
sform
med
icine
s man
ufac
turin
g.
Inte
grat
ion
Pre
dict
ive
Pro
duct
Des
ign
Pre
dict
ive
Pro
cess
Des
ign
Dev
elop
ing
Pat
hway
s fo
r P
erfo
rman
ce
Bas
ed M
anuf
actu
re
Mol
ecul
e
Dig
ital
Supp
ly
Mic
ro-
Fact
ory
Per
sona
lised
Pro
duct
s Su
pply
Esta
blish
ed in
201
1, C
ontin
uous
Man
ufac
turin
g an
d A
dvan
ced
Crys
talli
satio
n (C
MA
C)
is a
wor
ld c
lass
nat
iona
l fac
ility
for r
esea
rch
and
trai
ning
in a
dvan
ced
phar
mac
eutic
al
and
chem
ical
man
ufac
turin
g. S
ituat
ed w
ithin
the
Uni
vers
ity o
f Str
athc
lyde
’s Te
chno
logy
an
d In
nova
tion
Cent
re, C
MA
C w
orks
to a
ccel
erat
e th
e ad
optio
n of
con
tinuo
us
man
ufac
turin
g of
pha
rmac
eutic
als
and
tran
sfor
m th
e su
pply
cha
ins
of th
e fu
ture
. Alo
ng
with
CM
ACs
aca
dem
ic p
artn
ers,
indu
stry
Tie
r1 m
embe
rs in
clud
e G
SK, A
stra
Zene
ca,
Nov
artis
, Bay
er, L
illy,
Roc
he, T
aked
a an
d te
chno
logy
com
pani
es w
ho a
re a
ll w
orki
ng
toge
ther
to a
dvan
ce m
anuf
actu
ring
rese
arch
and
the
unde
rsta
ndin
g of
con
tinuo
us
man
ufac
turin
g. C
MA
C ha
s £1
0 M
illio
n fr
om E
PSRC
as
part
of t
he £
50 M
illio
n pr
ogra
m
to d
eliv
er th
e H
ub re
sear
ch p
rogr
amm
e, a
nd a
dditi
onal
pub
lic s
uppo
rt fr
om IU
K, S
FC,
SDI,
and
SE.
ww
w.c
mac
.com
£100
m fu
ndin
g po
rtfo
lio 2
011-
2016
Lead
ing
Tier
1 a
nd s
uppl
y ch
ain
part
ners
7 ye
ar E
PSR
C fu
ndin
g se
cure
in 2
017
as
Futu
re M
anuf
actu
ring
Hub
Pro
cess
dev
elop
men
t with
gra
m o
f mat
eria
l th
roug
h m
odel
ling
130
staf
f and
stu
dent
acr
oss
a ne
twor
k of
7
lead
ing
UK
uni
vers
ities
Impa
ct o
f tec
hnol
ogy
on n
ew m
edic
ines
an
d £1
bn s
avin
gs in
man
ufac
turi
ng
2016
ISP
E Fa
cilit
y of
the
Year
Win
ner
for
hub
at th
e U
nive
rsity
of S
trat
hcly
de
Med
icin
es M
anuf
actu
ring
Inno
vatio
n C
entr
e (M
MIC
) Ope
ratio
nal
7 Ti
er 1
par
tner
sG
SK, A
Z, N
ovar
tis, B
ayer
, Lill
y, R
oche
, Ta
keda
Impa
ct o
f tec
hnol
ogy
on n
ew m
edic
ines
an
d £1
bn s
avin
gs in
man
ufac
turi
ng
MM
IC p
roje
ct fr
ont e
nd s
tudy
and
G
over
nmen
t sup
port
Impa
ct o
f tec
hnol
ogy
on n
ew m
edic
ines
an
d £1
bn s
avin
gs in
man
ufac
turi
ng
CM
AC
Man
ufac
turi
ng In
nova
tion
Roa
dmap
Cur
rent
lyA
chie
ve in
Fut
ure
04 | Life and Chemical Sciences | Manufacturing Innovation
Med
icin
es M
anuf
actu
re
Inno
vatio
n Ce
ntre
(MM
IC)
CMAC
hav
e be
en w
orkin
g wi
th th
e Ce
ntre
for P
roce
ss
Inno
vatio
n (C
PI),
Med
icine
s Man
ufac
turin
g In
dust
rial
Partn
ersh
ip (M
MIP
) and
Sco
ttish
Ent
erpr
ise (S
E) to
m
ake
MM
IC a
reali
ty. M
MIC
will
offe
r pha
rmac
eutic
al co
mpa
nies t
he p
oten
tial t
o sa
ve ti
me,
save
capi
tal a
nd
redu
ce ri
sk. M
MIC
will
be a
fi rst
-in-cl
ass,
glob
al fa
cility
th
at o
ffers
a su
stain
able
and
fl exib
le m
eans
to ac
celer
ate
the
adop
tion
of e
mer
ging
and
nove
l man
ufac
turin
g
tech
nolo
gies
and
trans
form
pha
rma m
anuf
actu
ring.
M
MIC
will
cove
r the
end
-to-e
nd m
anuf
actu
ring
supp
ly ch
ain w
ithin
a bes
poke
, qua
lity d
riven
and
safe
en
viron
men
t. M
MIC
will
be an
ena
bler
in te
rms o
f tak
ing
adva
nces
in m
anuf
actu
ring
rese
arch
and
prov
iding
a fa
cility
for p
rovin
g co
ncep
ts b
efor
e lau
nchin
g th
em in
to
com
mer
cial o
pera
tions
.
Opt
imis
ed p
harm
aceu
tical
and
hig
h-va
lue
chem
ical
man
ufac
turi
ng o
pera
tions
acr
oss
the
valu
e ch
ain
whi
ch:
Are
eco
nom
ic, e
ffi ci
ent,
lean
and
w
orld
cla
ssA
llow
s re
duce
d tim
e to
mar
ket
Are
sus
tain
able
and
wea
lth
crea
ting
Del
iver
reg
ulat
ory
com
plia
nce
Und
erst
andi
ng o
f ‘be
tter
and
nov
el
part
icle
s’In
sigh
t int
o pa
rtic
le fo
rmat
ion
Impa
ct in
form
ulat
ion
and
qual
ity a
ttri
bute
s
Nov
el m
anuf
actu
ring
tec
hnol
ogie
s av
aila
ble
Opt
imis
atio
n of
pro
cess
es th
at c
an b
e co
ntro
lled
or a
dapt
ed
Supp
ortiv
e go
vern
men
tsC
olla
bora
tion
with
com
pani
esSt
rong
inno
vatio
n ne
twor
kSt
rong
UK
Pha
rma
base
Why
?B
enefi
ts
Pha
se 1
out
put d
isse
min
atio
n
Res
earc
h Ex
cell
ence
an
d In
tens
ity
Out
stan
ding
Sk
ills
D
evel
opm
ent
Exem
plar
y Tr
ansl
atio
n to
In
dust
ry
Wor
ld C
lass
Fa
cili
ties
Dev
elop
men
t of
MM
IC
Inte
grat
ed p
roce
ss a
nd m
odel
ling
from
syn
thes
is to
dru
g pr
oduc
tfr
om s
ynth
esis
to d
rug
prod
uct
Del
iver
am
bitio
us 7
yea
r G
rand
Cha
lleng
e m
anuf
actu
ring
res
earc
h pr
ogra
mm
e en
gagi
ng a
ll co
llabo
rato
rs
from
syn
thes
is to
dru
g pr
oduc
t
Dem
onst
rate
Dig
ital T
win
Impr
oved
man
ufac
turi
ng p
roce
ss a
nd
qual
ity w
ill b
enefi
t p
atie
nts
and
prod
ucer
s dr
ivin
g C
MAC
sus
tain
abili
ty
Dev
elop
men
t of w
orld
cla
ss fa
cilit
ies
will
en
able
inno
vatio
n ac
ross
pro
cess
and
en
hanc
e to
sup
port
Focu
s on
man
ufac
turi
ng tr
ansl
atio
n w
ill c
emen
t CM
AC s
tand
ing
as le
adin
g In
tern
atio
nal o
rgan
isat
ion
infl u
enci
ng
polic
y
Pro
duct
ion
of m
icro
fact
orie
s w
ill e
nabl
e fu
ture
pha
rmac
eutic
al m
anuf
actu
ring
and
cr
eate
jobs
MM
IC w
ill s
ave
time,
sav
e ca
pita
l and
de
-ris
k in
vest
men
t fro
m p
harm
aceu
tical
co
mpa
nies
Succ
essf
ul m
id te
rm r
evie
w
+ pr
epar
atio
n of
futu
re fu
ndin
g
Bes
t Man
ufac
turi
ng M
aste
rsfu
ture
fun
ding
Del
iver
aga
inst
com
pany
targ
ets
for
new
and
est
ablis
hed
Tier
1 m
embe
rs
Por
tfol
io o
f fun
dam
enta
l, ap
plie
d an
d tr
ansl
atio
nal m
anuf
actu
ring
re
sear
ch p
roje
cts
with
R&
D a
nd P
rodu
ctio
n gr
oups
Vibr
ant T
ier2
par
tner
eco
syst
em a
ddin
g va
lue
to r
esea
rch
hub,
Tie
r1 a
nd a
cade
mic
par
tner
s
Gro
win
g ap
plie
d re
sear
ch
prog
ram
me
‘fee
for
serv
ice’
‘CM
AC L
ab o
f the
Fut
ure’
Enha
nce
to s
uppo
rt s
cope
and
bre
adth
of s
ervi
ces
Fron
t end
stu
dyD
esig
n an
d de
fi niti
on
Con
stru
ctio
n
Full
com
mer
cial
de
ploy
men
t
Nur
ture
and
gro
w a
ll C
MAC
sta
ff a
nd r
esea
rche
rs th
roug
h ta
rget
ed tr
aini
ng
Hig
h va
lue
prod
ucts
res
ultin
g fr
om:
Ben
efi t
s fo
r pa
tient
s:
Hig
h le
vel i
mpa
ct o
f man
ufac
turi
ng r
esea
rch
prod
uced
thro
ugh:
2017
2018
2019
2020
Life and Chemical Sciences | Manufacturing Innovation | 05
Cellu
Com
p is
a dyn
amic
mat
erial
scien
ce co
mpa
ny
base
d in
Scot
land
that
dev
elops
hig
h pe
rform
ance
pr
oduc
ts b
ased
on
sust
ainab
le re
sour
ces.
They
ha
ve d
iscov
ered
the
exce
ptio
nal o
ppor
tunit
ies
offe
red
by m
ater
ials p
rodu
ced
from
non
-hy
droc
arbo
n fe
edst
ocks
. With
this
in m
ind, t
heir
visio
n is
to cr
eate
mat
erial
chan
ge fo
r goo
d.
Foun
ded
by D
r Dav
id H
epwo
rth an
d Dr
Eric
Wha
le,
Cellu
Com
p m
anuf
actu
res a
pro
duct
calle
d Cu
rran®
(G
aelic
for c
arro
t), co
nsist
ing o
f nan
o-ce
llulo
se
extra
cted
from
food
pro
cess
ing b
y-pr
oduc
ts an
d ha
s use
s acr
oss a
num
ber o
f sec
tors
. Cur
ran®
of
fers
exc
eptio
nal r
heol
ogica
l and
mec
hanic
al
prop
ertie
s for
appl
icatio
ns, s
uch
as p
aints
and
coat
ings,
pers
onal
care
, hom
e ca
re, c
osm
etics
, co
ncre
te, d
rillin
g flu
ids,
com
posit
es an
d ot
hers
.Th
eir in
itial
mar
ket f
ocus
is as
a pa
int ad
ditiv
e.
Inclu
ded
in pa
int fo
rmula
tion,
Cur
ran®
will
prev
ent
crac
king
and
incre
ase
the
scru
b re
sista
nce
of
paint
ed su
rface
s whil
st re
plac
ing u
p to
50%
of t
he
bind
er u
sed
in co
nven
tiona
l pain
ts.
Cellu
Com
p no
w op
erat
e fro
m a
stat
e of
the
art
man
ufac
turin
g fa
cility
in G
lenro
thes
, Fife
whe
re
they
hav
e inc
reas
ed p
rodu
ctio
n to
satis
fy a
healt
hy
dem
and
for t
his h
igh
tech
and
sust
ainab
le co
mpo
site
prod
uct.
The
com
pany
now
has
the
pote
ntial
to m
ake
up
to 4
00 to
nnes
of C
urra
n® a
year,
and
is pl
annin
g to
ups
cale
prod
uctio
n to
10,
000
tonn
es p
er ye
ar
with
in th
ree
year
s.
“It’s
take
n a l
ong
time
for t
he co
mpa
ny to
reac
h th
is po
int, w
here
we
have
a pr
oduc
t on
the
mar
ket,”
said
Cell
uCom
p CE
O C
hrist
ian K
emp-
Griffi
n. ”B
ut n
ow w
e’re
her
e, w
e’ll a
ccele
rate
gr
owth
very
quic
kly.”
He ad
ded:
“We
could
be
com
e a b
illion
-pou
nd co
mpa
ny.”
Incr
easi
ng a
war
enes
s of
IBC
ontr
ibut
e to
del
iver
£90
0M in
dust
ry b
y 20
25
Esta
blis
hmen
t of R
BP
C a
nd F
lexB
IO
equi
pmen
t cen
tres
In
vest
ing
in V
alue
Cha
ins
usin
g B
iolo
gy
Pro
vidi
ng a
cces
s to
a T
echn
ical
Net
wor
kSt
rate
gic
Lead
ersh
ip
Cre
ate
a di
vers
e an
d w
ell c
onne
cted
in
dust
rial
com
mun
ity
Skill
ed W
orkf
orce
Exte
nsiv
e in
dust
ry-l
ed s
kills
pro
gram
me
Dev
elop
ing
Valu
e C
hain
s
Pro
mot
e Sc
otla
nd o
n an
inte
rnat
iona
l sca
leA
ccel
erat
ing
Com
mer
cial
isat
ion
Cur
rent
lyA
chie
ve in
Fut
ure
IBio
IC M
anuf
actu
ring
Inno
vati
on R
oadm
ap “F
rom
con
cept
to a
dopt
ion,
en
ablin
g bi
obas
ed g
row
th.
IBio
IC’s
visio
n is
to c
reat
e a
trul
y di
stin
ctiv
e, w
orld
lead
ing
inno
vatio
n ce
ntre
for
indu
stria
l bio
tech
nolo
gy (I
B). W
e w
ill a
ccel
erat
e an
d de
-risk
the
deve
lopm
ent
of c
omm
erci
ally
via
ble,
sus
tain
able
sol
utio
ns fo
r hig
h-va
lue
man
ufac
turin
g in
ch
emist
ry-b
ased
and
life
sci
ence
sec
tors
. In
doin
g so
we
will
est
ablis
h an
inno
vatio
n an
d gr
owth
eng
ine
yiel
ding
sub
stan
tial e
cono
mic
impa
ct a
nd d
eliv
erin
g in
crea
sing
and
sust
aina
ble
wea
lth c
reat
ion,
pro
sper
ity a
nd e
mpl
oym
ent i
n Sc
otla
nd.
ww
w.ib
ioic
.com
06 | Life and Chemical Sciences | Manufacturing Innovation
Supp
ort t
he c
onst
ruct
ion
of b
espo
ke d
emon
stra
tion
plan
ts
Why
?B
enefi
ts
Stra
tegi
c Le
ader
ship
Dev
elop
ing
Valu
e Ch
ains
Inve
stin
g in
Va
lue
Chai
ns
usin
g B
iolo
gy
Skil
led
Wor
kfor
ce
Acc
eler
atin
g C
omm
erci
alis
atio
n
2017
2018
2019
2020
Pro
mot
e Sc
otla
nd o
n in
tern
atio
nal s
cale
C
reat
e co
mpe
lling
cas
e fo
r in
war
d in
vest
men
t
Bri
ng fl
agsh
ip in
vest
men
t to
Scot
land
Adv
ocat
e fo
r th
e in
dust
ry to
influ
ence
IB
frie
ndly
Gov
ernm
ent p
olic
y
Rai
se a
war
enes
s of
Sco
tlan
d’s
IB a
ctiv
ity
Incr
ease
IB a
war
enes
s th
roug
h N
etw
ork
Inte
grat
or p
roje
ct
Des
ign
and
man
age
awar
enes
s ev
ents
for
wid
er in
dust
ry
Rep
rese
nt c
ompa
ny m
embe
rs a
t EU
leve
l
Pro
vide
fund
ing
supp
ort f
or in
dust
ry/a
cade
mic
pro
ject
s
Pro
vide
men
tori
ng a
nd s
uppo
rt fo
r gr
owin
g bu
sine
sses
Pro
vide
acc
ess
to IB
IoIC
Tec
hnic
al N
etw
ork
Supp
ort a
nd s
pons
or c
olla
bora
tive
MSc
in IB
Supp
ort H
ND
in IB
thro
ugh
Col
lege
s
Pro
vide
acc
ess
and
supp
ort t
o R
BP
C
Pro
vide
acc
ess
and
supp
ort t
o Fl
exB
IO
Supp
ort d
evel
opm
ent o
f Mar
ine
Bio
proc
essi
ng C
entr
e
Supp
ort t
he e
xplo
itatio
n an
d de
velo
pmen
t of s
ynth
etic
bio
logy
str
engt
hs in
Sco
tlan
d
Coo
rdin
ate
acce
ss to
UK
faci
litie
s th
roug
h B
ioP
ilots
UK
Mai
ntai
n in
dust
ry d
rive
n P
hD p
rogr
amm
e
Con
trib
ute
to s
trat
egic
del
iver
y of
STE
M a
cros
s Sc
otla
nd D
evel
op p
art-
time
optio
n fo
r M
Sc
Incr
ease
tech
nica
l and
com
mer
cial
cap
abili
ties
thro
ugh
CP
D fo
r IB
indu
stry
Exte
nd p
roje
ct fo
cus
from
TR
L3-5
to
incl
ude
TRL5
-7
Cat
alys
e th
e es
tabl
ishm
ent o
f an
IB
Enab
le s
et-u
p of
IB in
vest
men
t fun
d
Expa
nd IB
ioIC
rea
ch in
to n
ew s
ecto
rs
Att
end
and
part
icip
ate
in e
vent
s ou
t with
mai
nstr
eam
sco
pe o
f IB
ioIC
Exte
nd te
chno
logy
sco
pe
Exte
nd s
uppl
y ch
ain
activ
ity
Con
nect
to E
U a
nd G
loba
l val
ue c
hain
s an
d w
ebs
Scot
land
has
a n
umbe
r of
com
peti
tive
ad
vant
ages
in d
evel
opin
g th
is s
ecto
r:
It is
sm
all a
nd w
ell c
onne
cted
wit
h ef
fect
ive
coll
abor
atio
n be
twee
n in
dust
ry,
acad
emia
and
gov
ernm
ent
It h
as a
ski
lled
wor
kfor
ce a
nd s
tron
g ac
adem
ic c
apab
iliti
es b
ased
on
exis
ting
in
dust
ry in
che
mic
al m
anuf
actu
ring
, en
gine
erin
g an
d re
finin
g w
hich
are
hig
hly
tran
sfer
rabl
e to
the
bioe
cono
my.
It h
as u
niqu
e na
tura
l res
ourc
es in
mar
ine,
in
dust
rial
and
mun
icip
al w
aste
s
It h
as e
stab
lishe
d ac
tive
IB c
ompa
nies
of
all
siz
es
It h
as p
hysi
cal i
nfra
stru
ctur
e at
G
rang
emou
th to
sig
nific
antl
y lo
wer
the
cost
of m
anuf
actu
re
1 2 3 4 5
Enha
nce
Scot
land
’s p
lace
as
a le
adin
g lo
catio
n fo
r IB
on
a gl
obal
sta
ge
Incl
ude
com
pani
es in
bro
ad s
uppl
y ch
ain
to
supp
ort c
ompa
nies
to d
eliv
er c
ompe
titiv
e IB
pro
duct
s an
d se
rvic
es
Supp
ortin
g an
d fu
ndin
g gr
owth
to a
llow
IB
dev
elop
men
t, co
mm
erci
alis
atio
n an
d ex
ploi
tatio
n
Inte
rdis
cipl
inar
y sk
ills
avai
labl
e to
sup
port
IB
com
pani
es
Supp
ort t
he d
evel
opm
ent a
nd
dem
onst
ratio
n of
new
tech
nolo
gies
and
m
anuf
actu
ring
pro
cess
es
Life and Chemical Sciences | Manufacturing Innovation | 07
Boot
h W
elsh
is a U
K En
gine
ering
Ser
vices
Com
pany
lo
cate
d in
Irvine
and
part
of th
e int
erna
tiona
l Clo
ugh
Grou
p. R
ecen
tly th
ey w
orke
d wi
th a
glob
al dr
inks
com
pany
, whic
h pr
oduc
es m
any w
ell e
stab
lishe
d br
ands
, ope
ratin
g ac
ross
200
site
s acr
oss 3
0 co
untri
es
glob
ally,
includ
ing d
istille
ries,
pack
aging
plan
ts,
ware
hous
es an
d co
oper
ages
.
Boot
h W
elsh
prov
ided
softw
are
mod
ifi cat
ions
to
exist
ing S
iemen
s PCS
7 Di
strib
uted
Con
trol S
yste
m fo
r
new
fi ltra
tion
line
and
man
ufac
ture
d a n
ew IO
pan
el.
Clien
t sof
twar
e te
sting
and
live
loop
chec
king
was
cond
ucte
d us
ing a
seco
nd p
lant c
ontro
ller,
purc
hase
d sp
ecifi c
ally f
or th
e pr
ojec
t, to
mini
mise
the
large
cost
s as
socia
ted
with
ext
ende
d pl
ant d
ownt
ime.
Boot
h W
elsh
prov
ided
ext
ensiv
e kn
owled
ge o
f the
sit
e an
d bu
sines
s and
Siem
ens s
olut
ion
partn
er st
atus
in
obta
ining
value
for m
oney
and
ongo
ing su
ppor
t fo
r the
ir PC
S7 sy
stem
. Also
seam
less i
n-ho
use
pane
l
man
ufac
ture
and
plan
t dow
ntim
e wa
s mini
mise
d to
2
days
by u
tilisi
ng a
seco
nd id
entic
al co
ntro
l sys
tem
. Be
ing se
para
te fr
om th
e liv
e sit
e sy
stem
and
a se
para
te IO
pan
el all
owed
fi eld
IO te
sting
to th
e ne
w IO
pan
el to
be
cond
ucte
d wi
thou
t disr
uptin
g ex
isting
op
erat
ions
. Wor
king
with
Boo
th W
elsh
resu
lted
in a
quick
pro
ject t
urna
roun
d wi
thin
6 m
onth
s whic
h wa
s ah
ead
of ti
me
by tw
o we
eks a
nd o
n bu
dget
.
Cur
rent
lyA
chie
ve in
Fut
ure
Off
line
lab
test
ing
Rea
l tim
e re
leas
e
Com
plex
ity in
dat
a pr
esen
tatio
nA
dapt
ive
proc
ess
cont
rol
Dep
ende
nce
on p
aper
sys
tem
sSy
nchr
onis
ed s
uppl
y ch
ain
Dis
para
te d
atab
ases
Rea
l tim
e an
alyt
ics
Man
ually
col
lect
ed d
ata
Embe
dded
qua
lity
cont
rol
Lim
ited
pred
ictiv
e m
odel
sM
odel
ling
& s
imul
atio
n
Aut
omat
ion
Man
ufac
turi
ng
Inno
vati
on R
oadm
ap
Indu
stry
4.0
Ti
mel
ine
Just
as
IT fu
ndam
enta
lly c
hang
ed th
e w
orkp
lace
dur
ing
the
1980
s/90
s, a
sile
nt
revo
lutio
n is
now
und
erw
ay th
at w
ill tr
ansf
orm
the
prod
uctiv
ity a
nd c
apab
ilitie
s of
Sc
otla
nd’s
busin
esse
s. A
utom
atio
n te
chno
logi
es c
an h
elp
com
pani
es s
igni
fi can
tly
boos
t the
spe
ed, a
ccur
acy
and
safe
ty o
f bus
ines
s pr
oces
ses.
The
‘fou
rth
indu
stria
l re
volu
tion’
has
arr
ived
.
This
new
revo
lutio
n is
bein
g en
able
d by
dat
a - a
dig
ital r
evol
utio
n dr
iven
by
adva
ncem
ents
in c
ompu
ting
and
robo
tics.
08 | Life and Chemical Sciences | Manufacturing Innovation
Aug
men
ted
Rea
lity:
Sup
erim
posi
ng c
ompu
ter
gene
rate
d im
ages
com
bine
d w
ith o
bjec
t rec
ogni
tion
to
user
’s v
iew
of t
he r
eal w
orld
, giv
ing
an in
tera
ctiv
e hy
brid
vie
w
Sim
ulat
ion:
Am
alga
mat
ion
of p
hysi
cal a
nd v
irtu
al e
ntiti
es to
mod
el, d
esig
n, s
imul
ate,
mon
itor
and
safe
guar
d ph
ysic
al
proc
esse
s in
a v
irtu
al e
nvir
onm
ent
Add
itive
Man
ufac
turi
ng: D
igita
l des
ign
data
is u
sed
to c
reat
e a
thre
e-di
men
sion
al o
bjec
t in
whi
ch la
yers
of m
ater
ial a
re
form
ed u
nder
com
pute
r co
ntro
l
Syst
ems
Inte
grat
ion:
A m
ore
cohe
sive
cro
ss c
ompa
ny c
olla
bora
tion,
ena
blin
g ho
rizo
ntal
and
ver
tical
dat
a in
tegr
atio
n ne
twor
ks p
rovi
ding
trul
y au
tom
ated
val
ue c
hain
s
Aut
onom
ous
Syst
ems:
An
obje
ct o
r pr
oces
s th
at c
an g
ain
info
rmat
ion
abou
t it’s
env
iron
men
t, ad
apt a
nd m
ake
deci
sion
s w
ithou
t the
nee
d fo
r hu
man
inte
rven
tion
Big
Dat
a: L
arge
dat
a se
ts th
at m
ay b
e an
alys
ed c
ompu
tatio
nally
to r
evea
l inc
onsi
sten
t pro
cess
per
form
ance
or
avai
labi
lity
and
visu
alis
e re
sult
s
Inte
rnet
of T
hing
s: T
he n
etw
orki
ng a
nd c
onne
ctiv
ity o
f sm
art d
evic
es to
ena
ble
data
col
lect
ion
and
exch
ange
Clo
ud C
ompu
ting:
Rem
ote
serv
er s
oftw
are
and
hard
war
e se
rvic
es u
sed
to s
tore
, man
age,
pro
cess
and
vis
ualis
e da
ta,
rath
er th
an a
loca
l ser
ver
Cyb
er S
ecur
ity: P
rote
ctio
n of
com
pute
r sy
stem
s fr
om th
eft o
r da
mag
e to
har
dwar
e, s
oftw
are
or in
form
atio
n an
d fr
om
disr
uptio
n of
the
serv
ices
pro
vide
d
Why
?B
enefi
ts
Trai
ning
and
up
Ski
llin
g
Pro
cess
En
gine
erin
g an
d D
esig
n
Vert
ical
and
H
oriz
onta
l In
tegr
atio
n
Mai
nten
ance
an
d D
iagn
osti
c M
onit
orin
g
Rea
l Tim
e D
ata
Visu
alis
atio
n an
d D
ata
Ana
lysi
s
Func
tion
al S
afet
y an
d Sa
fety
Sys
tem
s
2017
2018
2019
2020
Cont
ext
R
obus
t dat
a so
urce
R
educ
e tim
e fo
r an
alys
is a
nd p
rodu
ct
re
leas
e
Ben
efits
in e
mer
ging
tech
nolo
gy
Mai
n D
rive
rs
Scal
e up
R&
D to
man
ufac
turi
ng
Cyc
le ti
me
redu
ctio
n
Rob
ust,
repe
atab
le c
ontr
ol
Mov
e to
war
ds s
mal
l sca
le a
nd
co
ntin
uous
man
ufac
ture
Impo
rtan
ce
Supp
ort t
o &
ben
efits
from
new
proc
ess
tech
niqu
es
Hig
h va
lue
reso
urce
use
Impl
icat
ions
R
ealis
e pe
rfor
man
ce b
enefi
ts o
f new
te
chno
logi
es
Effic
ient
, low
ris
k us
e of
man
ufac
turi
ng
ad
vanc
es
Dat
a ha
s
Insp
ectio
n re
adin
ess
Si
mpl
ified
ope
rato
r in
terf
ace
To
be
prov
ided
on
dem
and
R
educ
ed c
ompl
exity
Smar
t Sys
tem
s
Pro
duct
ivity
impr
ovem
ents
up
20%
P
erfo
rm ta
sks
auto
nom
ousl
y
Effic
ient
pro
cess
rep
eata
bilit
y
Enri
ched
dig
ital p
lant
mod
els
St
anda
rd s
yste
m in
terf
aces
Flex
ible
and
Sca
labl
e m
anuf
actu
re
Por
tabl
e fo
r lo
cal/
regi
onal
use
M
odul
ar “
plug
and
pla
y” s
yste
ms
R
educ
ed s
yste
m v
alid
atio
n
Tech
nolo
gy fr
om R
&D
into
man
ufac
turi
ng
Enha
nce
Aut
omat
ion
Syst
ems
R
eal t
ime
rele
ase
test
ing
C
onsi
sten
t qua
lity
assu
ranc
e
Red
uced
def
ects
and
was
te
Pro
cess
rob
ustn
ess
R
educ
ed ti
me
to m
arke
t
Life and Chemical Sciences | Manufacturing Innovation | 09
Rosli
n Ce
lls w
as fo
unde
d in
2006
by t
he R
oslin
Inst
itute
with
the
supp
ort o
f the
Univ
ersit
y of
Edinb
urgh
, the
Sco
ttish
Nat
iona
l Blo
od Tr
ansfu
sion
Serv
ice an
d Sc
ottis
h En
terp
rise.
The
com
pany
initi
ally
focu
sed
on th
e de
velo
pmen
t of c
ell th
erap
ies an
d pl
urip
oten
t ste
m ce
lls fo
r app
licat
ions
in re
sear
ch,
drug
disc
over
y and
ther
apy.
Now
oper
ating
as R
oslin
Cell
The
rapi
es Lt
d, th
ey ar
e wo
rld le
ader
s in
the
deve
lopm
ent o
f cell
ther
apies
an
d pl
urip
oten
t ste
m ce
lls fo
r app
licat
ions
in re
sear
ch,
drug
disc
over
y and
ther
apy.
Rosli
n Ce
ll The
rapi
es
Ltd
prov
ide
integ
rate
d an
d cu
stom
-des
igne
d pr
oduc
t dev
elopm
ent a
nd m
anuf
actu
re se
rvice
so
lutio
ns fo
r cell
ular t
hera
pies
inte
nded
for c
linica
l tri
als.
With
an e
xper
ience
d an
d pr
ofes
siona
l Cell
Th
erap
y Dev
elopm
ent a
nd G
MP
oper
atio
ns te
ams
and
a cus
tom
des
igne
d M
HRA
licen
sed
GMP
Cellu
lar
Ther
apy F
acilit
y, th
ey o
ffer a
com
plet
e po
rtfol
io o
f se
rvice
s to
mat
ch cl
ient n
eeds
, fro
m p
rocu
rem
ent,
GMP
trans
latio
n, p
roce
ss an
d as
say d
evelo
pmen
t and
qu
alifi c
atio
n, te
chno
logy
tran
sfer,
GMP
man
ufac
ture
,
stor
age
and
dist
ribut
ion.
Ba
sed
at th
e Ed
inbur
gh B
ioQ
uarte
r, st
rong
links
are
held
with
a wi
de n
etwo
rk o
f res
earc
hers
, clin
ician
s an
d Re
gulat
ory A
genc
ies, p
rovid
ing a
stro
ng p
latfo
rm
in wh
ich to
supp
ort c
lient
s to
the
clinic
and
beyo
nd.
Thro
ugh
a stro
ng co
mm
itmen
t to
quali
ty an
d de
liver
ing o
utst
andi
ng an
d pe
rson
alise
d cu
stom
er
serv
ice, R
oslin
Cell
The
rapi
es is
well
plac
ed as
the
partn
er o
f cho
ice fo
r tho
se w
ishing
to m
anuf
actu
re
cell-b
ased
ther
apies
for c
linica
l tria
ls.
Cur
rent
lyA
chie
ve in
Fut
ure
Ensu
re g
row
th o
f app
ropr
iate
ly s
kille
d w
orkf
orce
Ensu
re a
sup
port
ive
fi sca
l la
ndsc
ape
and
secu
re jo
b gr
owth
Cap
ture
big
ger
shar
e of
glo
bally
acc
essi
ble
reve
nues
Se
t out
tale
nt m
anag
emen
t pla
n fo
r ce
ll an
d ge
ne th
erap
y
Ensu
re a
nnua
l gro
wth
con
tinue
sTa
rget
and
sec
ure
mob
ile in
vest
men
ts
Inve
st to
bui
ld a
nd g
row
Sco
tlan
d’s
oper
atio
nal a
nd s
ervi
ces
base
Esta
blis
h vi
able
rou
te to
mar
ket
Seve
ral l
icen
sed
ATM
P
man
ufac
turi
ng fa
cilit
ies
in
Scot
land
Mai
ntai
n sc
ienc
e an
d in
nova
tion
fund
ing
Pro
mot
e an
d se
cure
pos
ition
as
wor
ld c
lass
hub
Dev
elop
and
long
term
reg
ulat
ory
stra
tegy
Cel
l and
Gen
e Th
erap
y M
anuf
actu
ring
Inno
vati
on R
oadm
ap
Adv
ance
d th
erap
y m
edic
inal
pro
duct
s (A
TMPs
), in
clud
ing
brea
kthr
ough
cel
l and
ge
ne th
erap
ies,
offe
r unp
rece
dent
ed p
rom
ise in
are
as o
f hig
h un
met
med
ical
nee
d.
Scot
land
is a
lead
er in
med
ical
rese
arch
and
now
has
a re
cogn
ised
posit
ion
in th
e di
scov
ery,
dev
elop
men
t and
ser
vice
s as
soci
ated
with
adv
ance
d th
erap
ies.
This
emer
ging
indu
stry
is a
t a c
ritic
al s
tage
in m
ovin
g re
sear
ch in
to m
anuf
actu
red
prod
ucts
with
the
focu
s no
w o
n m
anuf
actu
ring
scal
e-up
in o
rder
to c
omm
erci
alise
th
ese
ther
apie
s. In
this
cont
ext,
Scot
land
has
the
oppo
rtun
ity to
sec
ure
its
posit
ion
as a
glo
bal h
ub fo
r dev
elop
ing
and
man
ufac
turin
g th
ese
cutt
ing
edge
th
erap
ies.
Thi
s ro
adm
ap c
lose
ly a
ligns
with
the
2016
repo
rt “
Adv
ance
d Th
erap
ies
Man
ufac
turin
g A
ctio
n Pl
an –
sec
urin
g an
d at
trac
ting
adva
nced
ther
apie
s m
anuf
actu
re in
the
UK”
del
iver
ed b
y th
e M
edic
ines
Man
ufac
turin
g In
dust
ry
Part
ners
hip.
10 | Life and Chemical Sciences | Manufacturing Innovation
Bui
ld o
n cu
rren
t fina
ncia
l sup
port
for
cell
and
gene
ther
apy
com
pani
es a
nd s
uppl
y ch
ain
taki
ng in
to
acco
unt t
he e
arly
pha
se o
f gro
wth
of p
oten
tially
cur
ativ
e th
erap
ies
Con
tinue
to e
ngag
e w
ith S
MEs
to e
ffec
tivel
y ut
ilise
exi
stin
g fin
anci
al in
cent
ives
in a
com
plex
land
scap
e
Bui
ld o
n sp
ecifi
c ex
pert
ise
with
in S
DI a
nd S
E to
ena
ble
stro
ng ta
rget
ing
of
man
ufac
turi
ng in
war
d in
vest
men
t opp
ortu
nitie
s, u
tilis
ing
rele
vant
ly e
xper
ienc
ed
Glo
bal S
cots
to p
rom
ote
Scot
tish
offe
ring
Iden
tify
fisca
l sup
port
for
inw
ard
inve
stm
ent a
nd c
reat
ion
of fl
exib
le fa
cilit
ies
Sust
aine
d si
gnifi
cant
fund
ing
mec
hani
sms
to s
uppo
rt b
usin
ess-
to-b
usin
ess
and
busi
ness
- to
-aca
dem
ia c
olla
bora
tion
aro
und
key
enab
ling
tech
nolo
gies
and
man
ufac
turi
ng
Con
side
r of
feri
ng n
ew fi
nanc
ial p
rodu
cts
to s
uppo
rt p
refe
rent
ial g
row
th o
f cel
l and
gen
e th
erap
y m
anuf
actu
ring
in S
cotl
and
Dev
elop
an
inte
grat
ed s
trat
egy
to d
evel
op th
e ta
lent
poo
l at m
ultip
le e
ntry
poi
nts
and
leve
rage
exi
stin
g ro
utes
incl
udin
g ap
pren
tices
hips
, PhD
stu
dent
ship
s an
d U
nive
rsity
trai
ning
mod
ules
Incr
ease
num
ber
of te
chni
cal s
peci
alis
t in
this
fiel
d sp
ecifi
cally
cel
l cul
ture
tech
nici
ans
and
qual
ity p
erso
nnel
Seed
fund
ing
to e
nabl
e es
tabl
ishm
ent o
f the
inte
grat
ed ta
lent
man
agem
ent p
lan
Fund
ing
initi
ativ
es to
ena
ble
grow
th in
vir
al v
ecto
r de
velo
pmen
t and
man
ufac
ture
pr
evio
usly
iden
tified
as
a tr
ansl
atio
nal b
arri
er
Secu
re a
Cel
l and
Gen
e Th
erap
y Tr
eatm
ent C
entr
e an
d in
corp
orat
ing
man
ufac
ture
via
the
Indu
stri
al S
trat
egy
Cha
lleng
e Fu
nd to
be
loca
ted
with
in S
cotl
and
Ensu
re e
ngag
emen
t of r
elev
ant o
rgan
isat
ions
to c
onsi
der
a su
stai
nabl
e fu
ndin
g m
odel
and
pat
hway
for
adop
tion
with
in
NH
S Sc
otla
nd a
nd to
sec
ure
man
ufac
turi
ng in
vest
men
t clo
se to
the
patie
nt b
ase
Stro
ng e
ngag
emen
t with
reg
ulat
ory
bodi
es to
ens
ure
a fo
rwar
d th
inki
ng a
nd p
ositi
ve r
egul
ator
y en
viro
nmen
t exi
sts
Ensu
re c
ompa
nies
in c
ell a
nd g
ene
ther
apy
and
supp
ly c
hain
com
pani
es a
re w
ell e
ngag
ed w
ith U
K in
itiat
ives
to a
ddre
ss th
e ch
alle
nge
of s
tand
ardi
satio
n in
this
em
erge
nt a
rea
Why
?B
enefi
ts
Mai
ntai
n an
d gr
ow th
e fi
scal
la
ndsc
ape
Targ
et a
nd
secu
re m
obile
in
vest
men
ts
Mai
ntai
n sc
ienc
e an
d in
nova
tion
fu
ndin
g
Set o
ut
end-
to-e
nd ta
lent
m
anag
emen
t pla
n
Esta
blis
h vi
able
ro
ute
to m
arke
t
Dev
elop
a lo
ng
term
reg
ulat
ory
stra
tegy
2017
2018
2019
2020
Off
er u
npre
cede
nted
pro
mis
e fo
r th
e lo
ng-t
erm
man
agem
ent a
nd e
ven
cure
of
dise
ase,
esp
ecia
lly
in a
reas
of h
igh
unm
et
med
ical
nee
d
Adv
ance
d th
erap
ies
are
driv
ing
an e
xcit
ing
and
revo
luti
onar
y ne
w p
arad
igm
in s
cien
ce a
nd
heal
thca
re
Scot
land
took
an
earl
y le
ad in
cap
turi
ng
adva
nced
ther
apy
med
ical
res
earc
h an
d no
w
has
a re
cogn
ised
lead
ing
inte
rnat
iona
l pos
itio
n in
the
disc
over
y an
d de
velo
pmen
t of a
dvan
ced
ther
apie
s
Emer
ging
indu
stry
is a
t a c
riti
cal s
tage
in
tran
slat
ing
this
res
earc
h in
to m
anuf
actu
red
prod
ucts
wit
h th
e fo
cus
now
on
plan
ning
m
anuf
actu
ring
sca
le-u
p in
ord
er to
co
mm
erci
alis
e th
ese
ther
apie
s
Bri
ngin
g to
geth
er S
cott
ish
inve
stm
ents
su
ch a
s H
ealt
h Sc
ienc
es S
cotl
and,
NH
S R
esea
rch
Scot
land
, NH
S Sc
otla
nd a
nd
SNB
TS a
nd le
adin
g te
chno
logy
-bas
ed
indu
stri
al p
artn
ers
Scot
land
was
sel
ecte
d as
the
loca
tion
to
cond
uct t
he U
K’s
firs
t app
rove
d AT
MP
st
em c
ell c
linic
al tr
ial a
nd a
lrea
dy h
as
acti
ve c
ell t
hera
pies
in c
linic
al p
ract
ice
Its
com
mer
cial
land
scap
e ha
s de
velo
ped
prom
isin
g ad
vanc
emen
ts in
ena
blin
g te
chno
logi
es th
at h
ave
guid
ed c
ell
func
tion
alit
y an
d cr
eate
d vi
able
cel
l th
erap
y pr
oduc
ts fi
t for
the
clin
ic
Supp
ort p
rodu
ct d
evel
opm
ent,
ch
arac
teri
zati
on a
nd p
oten
cy d
evel
opm
ent,
m
akin
g th
e re
gula
tory
pro
cess
muc
h ea
sier
Life and Chemical Sciences | Manufacturing Innovation | 11
Continuous Manufacturing and Advanced Crystallisation (CMAC) [email protected] +44 (0)141 548 450
Industrial Biotechnology Innovation Centre (IBioIC) www.ibioic.com [email protected]+44 (0) 141 548 5946
Scottish Enterprise Helpline: +44 (0) 845 607 8787 Email: [email protected] www.scottish-enterprise.com
www.chemicalsciencesscotland.com | www.lifesciencesscotland.com
Brochure compiled by Aisha Ijaz with support from SE and Skills Development Scotland through the Scotgrad Internship Programme.)
Life Sciences in
“In 40 years in the Life Science Industry I can’t remember a more exciting time for manufacturing. Increased funding and focus on innovation provides us with a great opportunity to accelerate the adoption of new technology to improve manufacturing productivity.”
Dr. Clive Badman OBEHead of PTS Pre Competitive Activities, GSK